Accurate 24-h urine cystine quantification for patients on cystine-binding thiol drugs

Charles C. Mikel1 · David S. Goldfarb2 · Amy Ponte3 · Katherine Steigelman3 · Sergey Latyshev1

Received: 29 July 2022 / Accepted: 22 September 2022 / Published online: 6 October 2022
© The Author(s) 2022

Abstract
Cystinuria is a rare disorder resulting in development of recurrent kidney stones, adversely affecting patient quality of life. The goal of cystinuria management is to reduce stone formation by increasing cystine solubility in urine, which includes lowering the urinary cystine level below its solubility limit. Treatment usually involves alkalinization of the urine and often requires initiating pharmacotherapy with a cystine-binding thiol drug (CBTD) such as tiopronin; however, proper dose adjustment requires accurate measurement of urinary cystine. The goal of this study was to validate a novel high-performance liquid chromatography tandem mass spectrometry (HPLC–MS/MS) method for quantification of cystine in the urine of patients with cystinuria receiving a CBTD. Urine samples were collected over 24 h from 24 patients and separated into 2 aliquots. Chromatographic separation of samples was conducted and separation of cystine from the cysteine-tiopronin drug complex was complete in < 3 min. The method was validated for accuracy, precision, linearity, limit of detection (LOD), and limit of quantification (LOQ). Mean accuracy range was 97.7–102.3%; intermediate precision was high with relative percent difference values calculated at 1.2–9.3%; the calibration curve resulted in a linear response throughout the concentration range ($R^2 = 0.998$); and the LOD and LOQ were 0.002 and 0.005 mg/mL, respectively. Mean (range) cystine concentrations measured were 111.10 (51.31–179.46) and 242.21 (61.14–741.80) g/L in Aliquots A and B, respectively. The HPLC–MS/MS method presented here indicates that urine cystine can be reliably quantified in patients receiving a CBTD.

Keywords Cystinuria · Kidney stones · Cystine-binding thiol drug · Liquid chromatography tandem mass spectrometry · Urinary cystine solubility

Introduction
Cystinuria is a rare genetic disorder of disrupted resorption of cystine and dibasic amino acids in the proximal tubule of the kidneys [1]. The resulting elevated urinary cystine levels lead to the development of recurrent kidney and bladder stones [2]. Recurrent stones adversely affect activities of daily living, emotional and mental health, and quality of life, and in addition, they confer a higher risk of developing chronic kidney disease (CKD), which has been reported in as many as 70% of patients with cystinuria [3–9].

The goal of cystinuria management is to increase cystine solubility. One contributor to this goal is reduction of the cystine concentration in the urine to below 250 mg/L (its solubility at a urinary pH of 7.0), which is the generally accepted solubility limit in patients to avoid stone formation. Urinary pH is an important determinant of cystine solubility, and solubility increases with increasing alkalinization (750 mg/L at pH 8.0) [7, 10]. Initial conservative management includes adequate fluid intake, dietary restrictions, and urinary alkalinization therapy [10, 11]. If these first-line therapies are not effective, or if a patient has a large, recurrent stone burden, the American Urological Association Guidelines recommend the use of cystine-binding thiol drugs (CBTDs) such as alpha-mercaptopropionyl glycine (tiopronin) [12]. Patients on CBTDs should be monitored through 24-h urine collections, and doses of CBTDs should
be adjusted to the lowest effective dose that maintains uri-
nary cystine levels < 250 mg/L [10].

Collection of the 24-h urine sample for evaluation of urine chemistry is the cornerstone of preventive therapy and is recommended for all cystine stone formers. Expert consensus recommendations suggest obtaining a 24-h urine sample 1–2 months after initiating dietary modification or pharmacotherapy. Additional urine samples should be collected periodically to assess changes produced by the therapy, with the goal of increasing solubility and reducing the urinary cystine concentration to < 250 mg/L at urinary pH > 7.0. Clinicians should also evaluate patient adherence as part of the follow-up plan [10]. However, management is not straightforward, as most cystine assays cannot reliably differentiate free cystine from the cysteine-thiol drug complexes in patients taking CBTDs [13, 14]. A cystine capacity test can provide reliable measurements but is impractical for routine clinical practice because of complexity and limited availability [14, 15]. Therefore, a valid, reliable, practical test is needed to quantify urinary cystine levels for patients on CBTDs, guide clinical decision-making, and minimize the risk of adverse events.

Previous methods used to quantify urinary cystine include solid-phase assays, colorimetric reactions, and chromatographic techniques, but these methods are limited in their ability to reliably distinguish cystine from thiol drug-cysteine complexes, complicating clinical interpretation of test results [14, 16, 17]. In a prior study, high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) was used to quantify cystine in conditionally immortalized human proximal tubular epithelial cells (ciPTEC) [18]. This fast and reliable assay shares similarities with the method described in this manuscript but analyzed cystine recovered from whole kidney cells instead of urine [18]. The goal of this study was to validate a novel HPLC–MS/MS method for quantification of cystine in the urine of patients with cystinuria receiving CBTDs.

Methods

Materials and equipment

The following chemicals, reagents, and instruments were used: primary HPLC–MS/MS instrumentation (Agilent Technologies, Inc.); polar column (Phenomenex, Inc.); analytical balance (Shimadzu Corporation); vortex mixer (Thermo Fisher Scientific); centrifuge (Restek Corporation); pipettors (Globe Scientific); high-performance liquid chromatography (HPLC)–grade water, acetonitrile, isopropanol, and methanol (Honeywell International, Inc.); formic acid and ammonium formate (Supelco); autosampler vials (Shimadzu Corporation); L-cystine (Sigma-Aldrich); R-Cysteine-R-Tiopronin (Travere Therapeutics, Inc.); DL-Cystine-2,2′,3,3′,3′-d6 (C/D/N Isotopes Inc.); and cotinine-d3 0.1 mg/mL in methanol (NGX).

Sample collection

As specified in the 24-h urine collection instructions, patients added 1 g thymol powder and 50 mg gentamicin powder as preservatives to the 24-h urine container before the first urine sample collection. Patients then discarded the first morning urine and began collecting specimens throughout the following 24 h. The final urine collection was conducted the next morning, and total urine volume was recorded by the patient. Approximately 100 mL of urine was transferred from the 4-L 24-h urine collection container to a sample urine cup labeled “A”. The remaining urine sample in the 24-h urine container was mixed with 7 g of sodium carbonate and shaken well. Following incubation for 30 min, the container was shaken again, and approximately 100 mL was poured into a sample urine cup labeled “B”. The samples were shipped overnight to a laboratory at room temperature and were then frozen and sent to the investigators.

The internal standard used for quantification of cystine was cystine-d6. Because no isotopic analogue was available for cysteine-tiopronin, cotinine-d3 was chosen as the surrogate internal standard due to its similar and unique properties. The internal standard was prepared as follows: 100 mg of cystine-d6 was dissolved into 100 mL of 1 N HCl (aq.) to produce a 1.0 mg/mL solution of cystine-d6. A 10× dilution of the commercially available 0.1 mg/mL solution of cotinine-d3 was prepared in 0.1 N HCl (aq.) to create a 0.01 mg/mL solution of cotinine-d3. Equal parts of the cystine-d6 and cotinine-d3 solutions were mixed to generate the internal standards solution.

A “dilute-and-shoot” HPLC–MS/MS method was utilized, wherein 20 µL of sample, calibrator, or quality control sample was added to a 2 mL HPLC vial. Next, 1400 µL of 0.1 N HCl (aq.) was added, followed by 80 µL of the internal standard mixture.

HPLC–MS/MS method

Mass spectrometry was conducted using an Agilent 6410 Triple Quadrupole HPLC–MS/MS system (Agilent Technologies, Inc.). HPLC was performed by injecting 10 µL samples into a C18 Polar Column (Phenomenex Luna® Omega 5 µm 100Å50 × 4.6 mm) and separated by an Agilent 1200 series binary pump system (Agilent Technologies, Inc.). Chromatographic separation was performed at a flow rate of 0.400 mL/min using a gradient elution program over 6.5 min. Eluents were 0.1% formic acid in water and 0.1% formic acid in acetonitrile.
Instrument control, data acquisition, and data processing were all performed using the Agilent MassHunter (v.7) software platform (Agilent Technologies, Inc.). Samples were introduced via a positive electrospray ionization with the following source conditions: gas temperature of 300 °C, gas flow rate of 10 L/min, nebulizer pressure of 15 psi, and capillary voltage of 3500 V. After optimization, two multiple reaction monitoring transitions were selected for cystine and the cysteine-tiopronin complex, whereas 1 was selected for each internal standard. Spectra were scanned over the mass/charge number (m/z) range of 74.1–152.0 atomic mass units and were generated by collision-induced dissociation between 8 and 36 V.

The aim of optimizing the HPLC–MS/MS method was to achieve analyte separation and detection within 3 min. The method was developed in accordance with Food and Drug Administration (FDA) Bioanalytical Method Validation Guidance for Industry.

Cystine quantification

Calibration, linearity, and range

A 6-point calibration curve with target concentrations ranging from 0.03 to 1.00 mg/mL was prepared. Limits of detection (LOD) and limits of quantification (LOQ) were calculated using the standard deviation (SD) of the y-intercepts of the calibration curve. A regression analysis with 99% confidence level, which included determination of SD, was performed using the Microsoft Excel Data Analysis ToolPak add-in (Microsoft Corporation, Inc.). LOD was calculated as 3 SDs and LOQ as 10 SDs.

Accuracy and precision

Accuracy and repeatability were determined using six replicates of each target concentration calibrator. Accuracy was assessed using mean accuracy percentage, while repeatability was assessed using the calculated SD and the coefficient of variation (CV). Intermediate precision of the current HPLC–MS/MS method was investigated using 3 sets of calibrators prepared over 3 days by different chemists. The second and third set of calibrators were run as controls against the first set. Intermediate precision was assessed using relative percent difference (RPD).

Assessment of potential interferences and matrix effects

The susceptibility of the current method to interference from exogenous compounds was assessed using 9 mixtures containing commonly used over-the-counter, prescription, and illicit drugs. Susceptibility to interference from endogenous compounds was evaluated by 15 collections of 24-h urine samples from individuals without cystinuria. All samples were run through the HPLC–MS/MS process and tested for the occurrence of false positives.

Although the use of cystine-D6 as an internal standard was expected to reduce the possibility of signal enhancement or suppression because of matrix effects, testing nevertheless was performed to screen for these potential effects. Cystine solution (2 mg/mL) was added 1:1 (volume:volume) to a sample of blank urine and each of the 9 interference mixtures, and matrix effects were subsequently evaluated.

Patient samples

The 24-h urine samples taken from 24 patients receiving a CBTD were provided for testing by Travere Therapeutics (San Diego, CA). Upon collection, an aliquot of each patient sample was removed (Cup A), and the remaining specimen was treated with excess sodium carbonate (Cup B) to increase urinary pH and solubilize cystine. All 48 samples were analyzed for cystine using the current HPLC–MS/MS method.

Results

HPLC–MS/MS method

Chromatographic separation of cystine from the cysteine-tiopronin drug complex was achieved in < 3 min (Fig. 1A).

Cystine quantification

Calibration, linearity, and range

The calibration curve resulted in a linear response throughout the concentration range ($R^2 = 0.998$; Fig. 2). The LOD and LOQ were 0.002 and 0.005 mg/mL, respectively.

Accuracy and precision

Six replicates of calibrators were used to determine accuracy for each target concentration. For each target concentration, mean accuracy ranged from 97.7 to 102.3%, and CVs ranged from 1.2 to 3.3% (Table 1). Precision was defined as a statistical determination of the closeness of agreement between independent test results obtained under specific conditions (the classes of repeatability and intermediate precision apply to the analyses presented here). Assessment of repeatability was conducted using 6 determinations of calibrators, and results were used to calculate the SD and CV of the calibration curve for cystine quantification. The RPD ranged from 1.2 to 9.3%, indicating intermediate precision was high.
Assessment of potential interferences and matrix effects

No false positives were observed for exogenous or endogenous compounds. A significant matrix effect was observed in 1 interference mixture, which contained (-)-cotinine, (-)-nicotine, acetaminophen, caffeine, ibuprofen, naproxen, phentermine, and R,R(-)-pseudoephedrine.

Patient samples

Mean cystine concentrations were 111.10 g/L (range 51.31–179.46 g/L) and 242.21 g/L (range 61.14–741.80 g/L) in Aliquots A and Aliquots B, respectively (Fig. 1B; Table 2).
Discussion

Urine supersaturation is strongly correlated with stone mineral composition, and treatments designed for stone prevention decrease supersaturation values [19]. Strategies to prevent stone formation either reduce the absolute amount of cystine or increase its solubility in urine [20]. Medical therapies for cystine stone prevention include increasing fluid intake to 4 L or more per day, limiting sodium consumption to ≤ 2300 mg/day, ingesting a diet low in animal protein, and utilizing potassium citrate therapy to increase urinary pH to 7.0 [11, 12, 21–23]. If conservative management fails, treatment with CBTDs should be initiated, and patients should be monitored periodically with laboratory testing of blood and urine for potential adverse effects, metabolic response, and adherence to prescribed regimens [12]. Adverse events observed during tiopronin therapy include gastrointestinal and dermatological effects, elevations in liver enzymes, and hematologic abnormalities, such as anemia [12, 24]. In addition to monitoring urinary cystine output, analysis of urine chemistries is essential for effective patient care. The composition of urinary analytes can guide treatment choices and provide feedback on treatment efficacy over time. Monitoring changes in liver enzymes, urinary protein excretion, and complete blood cell count can allow the clinician to adjust therapy as needed [20, 22].

In the management of patients with cystinuria, monitoring cystine in the urine can assist clinicians in assessing the efficacy of therapy [11]. Proper adjustment of CBTD dosing is based on the quantification of total cystine in the urine, but methods to measure cystine and cystine solubility have limitations. Historically, urinary cystine measurement has been inaccurate, as quantification methods for routine testing have either been too complex or lack discernment in distinguishing cystine from CBTD–cysteine disulfide compounds. Colorimetric reactions used to measure free sulfhydryl groups in many cystine assays are unable to distinguish cystine from soluble cysteine-thiol drug complexes (formed by CBTDs), so these cystine measurements are unreliable [25]. Although the HPLC technique is able to distinguish between the two, sample preparation in this method may disrupt the cysteine-thiol drug complex, which also leads to inaccurate measurements [25]. In addition, calculating cystine supersaturation is unreliable because pH levels affect cystine solubility [25, 26]. The Litholink assay offered by the Litholink Corp. (Chicago, IL) for determination of cystine capacity measures the solubility of preformed cystine crystals added to patient urine samples, and the results can show a correlation with stone activity; however, the test lacks sensitivity [11, 27].

| Table 1 | Accuracy and precision for cystine quantification |
|---------|-------------------------------------------------|
| Sample no. | Target concentration (mg/mL) | Mean calculated concentration (mg/mL), n = 6 | Mean accuracy (%) | SD (mg/mL) | CV (%) |
| 1       | 0.0313                             | 0.0315 | 100.7 | 0.0005 | 1.6 |
| 2       | 0.0625                             | 0.0620 | 99.1  | 0.0020 | 3.3 |
| 3       | 0.1250                             | 0.1244 | 99.5  | 0.0015 | 1.2 |
| 4       | 0.2500                             | 0.2443 | 97.7  | 0.0058 | 2.4 |
| 5       | 0.5000                             | 0.5029 | 100.6 | 0.0062 | 1.2 |
| 6       | 1.0000                             | 1.0231 | 102.3 | 0.0231 | 2.3 |

| Table 2 | Measurement of cystine in 24-h urine samples of patients with cystinuria receiving a CBTD |
|---------|----------------------------------------------------------------------------------|
| Sample no. | Measured concentration of cystine (g/L) | Aliquot A | Aliquot B<sup>a</sup> |
| 1       | 128.48                             | 222.62 |
| 2       | 135.72                             | 147.58 |
| 3       | 130.88                             | 741.80 |
| 4       | 112.82                             | 144.84 |
| 5       | 101.36                             | 120.29 |
| 6       | 145.64                             | 196.47 |
| 7       | 139.06                             | 227.47 |
| 8       | 121.87                             | 312.05 |
| 9       | 57.91                              | 186.92 |
| 10      | 112.42                             | 134.02 |
| 11      | 82.35                              | 90.51 |
| 12      | 69.51                              | 122.07 |
| 13      | 138.96                             | 551.10 |
| 14      | 179.46                             | 333.23 |
| 15      | 99.53                              | 181.15 |
| 16      | 61.42                              | 64.82 |
| 17      | 56.00                              | 71.38 |
| 18      | 122.77                             | 242.63 |
| 19      | 143.43                             | 254.35 |
| 20      | 128.67                             | 650.22 |
| 21      | 51.31                              | 61.14 |
| 22      | 119.87                             | 464.59 |
| 23      | 110.98                             | 150.59 |
| 24      | 116.07                             | 141.07 |
| Mean    |                                   | 111.10 | 242.21 |

<sup>a</sup>Aliquot B was an alkalinized portion of the 24-h urine collection
The HPLC–MS/MS method reported here provides an alternative to laboratory testing offered by Litholink.

Limitations of the study include the small patient sample size (cystinuria is a rare disease) and lack of assessment of clinical outcome. Methodological limitations may be related to patient collection, freezing and shipping between laboratories, pH adjustment to Cup B with sodium carbonate, and freshness of the 24-h urine samples at the time of analysis.

Conclusions

The HPLC–MS/MS method described here was validated as an effective technique to reliably quantify urinary cystine in patients receiving CBTDs. Optimal cystine control can help prevent future formation of kidney stones by CBTD dose adjustments made based on these results. Offering patients and providers an improved testing methodology can provide insights into patient response to treatment with the ultimate goal of preventing kidney stones.

Acknowledgements

This study was funded by Travere Therapeutics, Inc. The authors thank Nicole Day, Ph.D., and Stephen Bublitz, ELS, of MedVal Scientific Information Services, LLC, for medical writing and editorial assistance, which were funded by Travere Therapeutics, Inc. This manuscript was prepared according to the International Society for Medical Publication Professionals’ “Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3”. This research was conducted in compliance with the Declaration of Helsinki as currently amended.

Author contributions

KS and AP were responsible for study concept and design. KS and AP provided study materials. CCM and SL collected, analyzed, and interpreted the data. All authors were involved in critically revising the manuscript, and all reviewed the final manuscript and gave approval for submission.

Declarations

Conflict of interests

CM: Employee of Nightmaker Science, LLC DG: Research funding, Travere; Owner, Moonstone Nutrition Inc. AP: Current employee and stockholder of Travere Therapeutics, Inc. KS: Current employee and stockholder of Travere Therapeutics, Inc. SL: Employee of Nightmaker Science, LLC.

Data sharing statements

The data used for the analyses in this manuscript are available on request from Travere Therapeutics, Inc., San Diego, CA.

Ethics approval

Patient samples were de-identified and consent was obtained prior to collection.

Role of sponsor

Travere Therapeutics, Inc, provided financial and material support for the research and, with the assistance of study investigators, monitored the conduct of the study, collected data from the investigative centers, and analyzed the data. Travere Therapeutics, Inc, also consulted with advisors and study investigators on the study design and assisted the authors in preparation and review of the manuscript. Travere Therapeutics, Inc, provided funding for professional medical writing and editorial assistance to MedVal Scientific Information Services, Princeton, NJ.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Prot-Bertoye C, Lebbah S, Daudon M, Tostivint I, Bataille P, Bridoux F, Brignon P, Choquenet C, Cochat P, Combe C, Conort P, Decramer S, Doré B, Dussol B, Essig M, Gaunez N, Joly D, Le Toquin-Bernard S, Méjean A, Meria P, Morin D, N’Guyen HV, Noël C, Normand M, Pietak M, Ronco P, Saussine C, Tsimaratos M, Friedlander G, Traxer O, Knebelmann B, Courbebaisse M (2015) CKD and its risk factors among patients with cystinuria. Clin J Am Soc Nephrol 10:842–851
2. Woodard LE, Welch RC, Veach RA, Beckermann TM, Sha F, Weinman EJ, Ikizler TA, Tischfeld JA, Sahota A, Wilson MH (2019) Metabolic consequences of cystinuria. BMC Nephrol 20:227
3. Penniston KL, Nakada SY (2016) Treatment expectations and health-related quality of life in stone formers. Curr Opin Urol 26:50–55
4. Angell J, Bryant M, Tu H, Goodman M, Pattaras J, Ogan K (2012) Association of depression and urolithiasis. Urology 79:518–525
5. Parr JM, Desai D, Winkle D (2015) Natural history and quality of life in patients with cystine urolithiasis: a single centre study. BJU Int 116(suppl 3):31–35
6. Modersitzki F, Pizzi L, Grasso M, Goldfarb DS (2014) Health-related quality of life (HRQoL) in cystine compared with non-cystine stone formers. Urolithiasis 42:53–60
7. Biyani CS, Cartledge JJ (2006) Cystinuria—diagnosis and management. EAU EBU Update Ser 4:175–183
8. Lindell A, Denneberg T, Granerus G (1997) Studies on renal function in patients with cystinuria. Nephron 77:76–85
9. Modersitzki F, Goldfarb DS, Goldstein RL, Sur RL, Penniston KL (2020) Assessment of health-related quality of life in patients with cystinuria on tiopronin therapy. Urolithiasis 48:313–320
10. Eisner BH, Goldfarb DS, Baum MA, Langman CB, Curhan GC, Preminger GM, Lieske JC, Pareek G, Thomas K, Zisman AL, Papagiannopoulos D, Sur RL (2020) Evaluation and medical management of patients with cystine nephrolithiasis: a consensus statement. J Endourol 34:1103–1110
11. Servais A, Thomas K, Dello Strologo L, Sayer JA, Bekri S, Bertholet-Thomas A, Bultitude M, Capolongo G, Cerkauksiene R, Daudon M, Doizi S, Gillion V, Gracia-Garcia S, Halbritter J, Heidet L, van den Heijkant M, Lemoine S, Knebelmann B, Emma F, Levchenko E (2021) Cystinuria: clinical practice recommendation. Kidney Int 99:48–58
12. Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk
13. Daga S, Palit V, Forster JA, Biyani CS, Joyce AD, Dimitrova AB (2021) An update on evaluation and management in cystinuria. Urolithiasis 149:70–75
14. Goldfarb DS, Coe FL, Asplin JR (2006) Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int 69:1041–1047
15. Mikel CC (2021) Accurate 24-hour urine cystine quantification for patients on cystine-binding thiol drugs (poster). Presented at WsAUA 97th annual meeting, Oct 30–Nov 4, 2021, Indian Wells, CA
16. Coe FL, Clark C, Parks JH, Asplin JR (2001) Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J Urol 166:688–693
17. Birwé H, Hesse A (1991) High-performance liquid chromatographic determination of urinary cysteine and cystine. Clin Chim Acta 199:33–42
18. Jamalpoor A, Sparidans RW, Pou Casellas C, Rood JMJ, Joshi M, Masereeuw R, Janssen MJ (2018) Quantification of cystine in human renal proximal tubule cells using liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 32:e4238
19. Parks JH, Coward M, Coe FL (1997) Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int 51:894–900
20. Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, Palacín M (2010) Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 6:424–434
21. Kok DJ, Iestra JA, Doorenbos CJ, Papapoulos SE (1990) The effects of dietary excesses in animal protein and in sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men. J Clin Endocrinol Metab 71:861–867
22. Goldfarb DS (2014) How to build a kidney stone prevention clinic. In: Grasso M, Goldfarb DS (eds) Urinary stones: medical and surgical management, 1st edn. Wiley, Hoboken, pp 1–12
23. Lingeman J, Mardis H, Kahnoski R, Goldfarb DS, Lacy S, Grasso M, Scheinman SJ, Parks JH, Asplin JR, Coe FL (1998) Medical reduction of stone risk in a network of treatment centers compared to a research clinic. J Urol 160:1629–1634
24. Pak CY, Sakhaee K, Fuller C (1986) Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 30:422–428
25. Sumorok N, Goldfarb DS (2013) Update on cystinuria. Curr Opin Nephrol Hypertens 22:427–431
26. Nakagawa Y, Asplin JR, Goldfarb DS, Parks JH, Coe FL (2000) Clinical use of cystine supersaturation measurements. J Urol 164:1481–1485
27. Friedlander JL, Antonelli JA, Canvasser NE, Morgan MSC, Mollengarden D, Best S, Pearle MS (2018) Do urinary cystine parameters predict clinical stone activity? J Urol 199:495–499

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.